AIM ImmunoTech annual revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AIM ImmunoTech Revenue Growth & History (AIM)
AIM ImmunoTech reported $88,000 in revenue for fiscal 2025, a decrease of 48.24% from the previous fiscal year.
View full AIM ImmunoTech company overviewAIM ImmunoTech annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $88,000 | −$82,000 | −48.24% |
| 2024 | 2024-12-31 | $170,000 | −$32,000 | −15.84% |
| 2023 | 2023-12-31 | $202,000 | $61,000 | +43.26% |
| 2022 | 2022-12-31 | $141,000 | $6,000 | +4.44% |
| 2021 | 2021-12-31 | $135,000 | −$28,000 | −17.18% |
| 2020 | 2020-12-31 | $163,000 | $23,000 | +16.43% |
| 2019 | 2019-12-31 | $140,000 | −$227,000 | −61.85% |
| 2018 | 2018-12-31 | $367,000 | −$70,000 | −16.02% |
| 2017 | 2017-12-31 | $437,000 | $345,000 | +375.00% |
| 2016 | 2016-12-31 | $92,000 | −$41,000 | −30.83% |
| 2015 | 2015-12-31 | $133,000 | −$64,000 | −32.49% |
| 2014 | 2014-12-31 | $197,000 | $47,000 | +31.33% |
| 2013 | 2013-12-31 | $150,000 | −$63,000 | −29.58% |
| 2012 | 2012-12-31 | $213,000 | $52,000 | +32.30% |
| 2011 | 2011-12-31 | $161,000 | $26,000 | +19.26% |
| 2010 | 2010-12-31 | $135,000 | $24,000 | +21.62% |
| 2009 | 2009-12-31 | $111,000 | — | — |
AIM ImmunoTech quarterly revenue
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $26,000 | $1,000 | +4.00% |
| Q1 2026 | 2026-03-31 | $22,000 | $6,000 | +37.50% |
| Q4 2025 | 2025-12-31 | $21,000 | −$24,000 | −53.33% |
| Q3 2025 | 2025-09-30 | $26,000 | −$9,000 | −25.71% |
| Q2 2025 | 2025-06-30 | $25,000 | −$25,000 | −50.00% |
| Q1 2025 | 2025-03-31 | $16,000 | −$24,000 | −60.00% |
| Q4 2024 | 2024-12-31 | $45,000 | −$20,000 | −30.77% |
| Q3 2024 | 2024-09-30 | $35,000 | −$11,000 | −23.91% |
| Q2 2024 | 2024-06-30 | $50,000 | $8,000 | +19.05% |
| Q1 2024 | 2024-03-31 | $40,000 | −$9,000 | −18.37% |
| Q4 2023 | 2023-12-31 | $65,000 | $8,000 | +14.04% |
| Q3 2023 | 2023-09-30 | $46,000 | $25,000 | +119.05% |
| Q2 2023 | 2023-06-30 | $42,000 | $12,000 | +40.00% |
| Q1 2023 | 2023-03-31 | $49,000 | $16,000 | +48.48% |
| Q4 2022 | 2022-12-31 | $57,000 | $6,000 | +11.76% |
| Q3 2022 | 2022-09-30 | $21,000 | −$12,000 | −36.36% |
| Q2 2022 | 2022-06-30 | $30,000 | $7,000 | +30.43% |
| Q1 2022 | 2022-03-31 | $33,000 | $5,000 | +17.86% |
| Q4 2021 | 2021-12-31 | $51,000 | $9,000 | +21.43% |
| Q3 2021 | 2021-09-30 | $33,000 | −$3,000 | −8.33% |
| Q2 2021 | 2021-06-30 | $23,000 | −$17,000 | −42.50% |
| Q1 2021 | 2021-03-31 | $28,000 | −$17,000 | −37.78% |
| Q4 2020 | 2020-12-31 | $42,000 | — | — |
| Q3 2020 | 2020-09-30 | $36,000 | −$25,000 | −40.98% |
| Q2 2020 | 2020-06-30 | $40,000 | $11,000 | +37.93% |
| Q1 2020 | 2020-03-31 | $45,000 | — | — |
| Q3 2019 | 2019-09-30 | $61,000 | $23,000 | +60.53% |
| Q2 2019 | 2019-06-30 | $29,000 | −$4,000 | −12.12% |
| Q4 2018 | 2018-12-31 | $240,000 | $190,000 | +380.00% |
| Q3 2018 | 2018-09-30 | $38,000 | −$52,000 | −57.78% |
| Q2 2018 | 2018-06-30 | $33,000 | −$180,000 | −84.51% |
| Q1 2018 | 2018-03-31 | $56,000 | −$28,000 | −33.33% |
| Q4 2017 | 2017-12-31 | $50,000 | $34,000 | +212.50% |
| Q3 2017 | 2017-09-30 | $90,000 | $68,000 | +309.09% |
| Q2 2017 | 2017-06-30 | $213,000 | $198,000 | +1320.00% |
| Q1 2017 | 2017-03-31 | $84,000 | $45,000 | +115.38% |
| Q4 2016 | 2016-12-31 | $16,000 | −$11,000 | −40.74% |
| Q3 2016 | 2016-09-30 | $22,000 | −$1,000 | −4.35% |
| Q2 2016 | 2016-06-30 | $15,000 | −$32,000 | −68.09% |
| Q1 2016 | 2016-03-31 | $39,000 | $3,000 | +8.33% |
| Q4 2015 | 2015-12-31 | $27,000 | −$13,000 | −32.50% |
| Q3 2015 | 2015-09-30 | $23,000 | −$22,000 | −48.89% |
| Q2 2015 | 2015-06-30 | $47,000 | $11,000 | +30.56% |
| Q1 2015 | 2015-03-31 | $36,000 | −$40,000 | −52.63% |
| Q4 2014 | 2014-12-31 | $40,000 | $4,000 | +11.11% |
| Q3 2014 | 2014-09-30 | $45,000 | $9,000 | +25.00% |
| Q2 2014 | 2014-06-30 | $36,000 | $0 | 0.00% |
| Q1 2014 | 2014-03-31 | $76,000 | $34,000 | +80.95% |
| Q4 2013 | 2013-12-31 | $36,000 | −$17,000 | −32.08% |
| Q3 2013 | 2013-09-30 | $36,000 | −$3,000 | −7.69% |
| Q2 2013 | 2013-06-30 | $36,000 | −$13,000 | −26.53% |
| Q1 2013 | 2013-03-31 | $42,000 | −$30,000 | −41.67% |
| Q4 2012 | 2012-12-31 | $53,000 | $15,000 | +39.47% |
| Q3 2012 | 2012-09-30 | $39,000 | −$6,000 | −13.33% |
| Q2 2012 | 2012-06-30 | $49,000 | $13,000 | +36.11% |
| Q1 2012 | 2012-03-31 | $72,000 | $30,000 | +71.43% |
| Q4 2011 | 2011-12-31 | $38,000 | $11,000 | +40.74% |
| Q3 2011 | 2011-09-30 | $45,000 | $10,000 | +28.57% |
| Q2 2011 | 2011-06-30 | $36,000 | −$5,000 | −12.20% |
| Q1 2011 | 2011-03-31 | $42,000 | $10,000 | +31.25% |
| Q4 2010 | 2010-12-31 | $27,000 | — | — |
| Q3 2010 | 2010-09-30 | $35,000 | — | — |
| Q2 2010 | 2010-06-30 | $41,000 | — | — |
| Q1 2010 | 2010-03-31 | $32,000 | — | — |
AIM ImmunoTech revenue growth trends
Over the last five reported fiscal years, revenue declined from $163,000 to $88,000, a compound annual decline of 11.60%. AIM ImmunoTech's latest reported quarter, Q2 2026, generated $26,000 in revenue, an increase of 4.00% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review AIM ImmunoTech source filings ↗